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OX40 (CD134, TNFRSF4), a member of the tumor
necrosis factor receptor (TNFR) superfamily is expressed
on activated CD4+ and CD8+ T cells. In pre-clinical
tumor models, agonist OX40 antibody (aOX40) therapy
is often successful at treating small tumors but is less
effective once the tumors have become established. For
a tumor immunotherapy to be successful it will most
likely require not only an agonist to boost effector
T cell function but also an antagonist to eliminate
T cell suppression. In this study, we show that agonist
OX40 antibody synergizes with an orally bioavailable
inhibitor of TGF-b (SM16) to elicit complete regression
of large established tumors, resulting in long-term survi-
val in 40-85% of aOX40/SM16 treated mice in two
murine tumor models. Evaluation of tumor infiltrating
T cells showed that SM16/aOX40 dual therapy resulted
in an increase in OX40 and Granzyme B-expressing
CD8+ T cells undergoing proliferation and which pro-
duced greater levels of IFNg. We also found that this
dual treatment led to an increase in pSTAT3 staining in
both CD4+ and CD8+ T cells isolated from tumors.
Therefore, we tested whether deletion of STAT3 in
OX40 expressing cells would impact this potent combi-
nation therapy, since others have shown that pSTAT3
up-regulation is detrimental to T cell function within
the tumor microenvironment. Surprisingly, deletion of
STAT3 decreased the therapeutic efficacy of this combi-
nation therapy, suggesting that immune enhancement of
T cells within tumor-bearing mice is reliant on signals
through STAT3 to gain their full therapeutic potential.
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